Prof. Rachela Popobzer from the Faculty of Engineering and the Institute for Nanotechnology and Advanced Materials at Bar Ilan University won a grant of 150 euros, for research aimed at making drug treatment more efficient and targeted
What will the next generation of cancer treatment drugs look like? What will make them more efficient and focused? The European Union is investing in the implementation of an innovative Israeli project, based on gold nanoparticles, for more effective treatment of various types of cancer, including breast cancer. Behind the research stands Prof. Rachela Popobzer, deputy dean Kofkin Faculty of Engineering and a leading researcher inInstitute for Nanotechnology and Advanced Materials at Bar-Ilan University. Prof. Popovtzer's innovative project, called Golden-ADC, offers a new concept for the combination of antibodies and chemotherapy drugs in the treatment of tumors, such as those that characterize breast cancer.
Prof. Popobzer's patent is based on gold nanoparticles coated with insulin, which are used as an innovative platform for transporting antibody-based drugs (ADC) to the growth areas. The use of gold nanoparticles makes it possible to overcome a number of challenges that until now have faced biological treatment, including the way of binding between the drug and the antibody. This significantly improves the effectiveness of the treatment. "As part of a project Golden-ADC, we see before our eyes the achievement of significant progress in the development of the technology, through the demonstration of the proof of concept that combines efficiency and safety in triple-negative breast cancer models", Prof. Popobzer notes.
The European Research Council also believes in Prof. Popobzer's project, and therefore awarded him a grant EIC (Proof of Concept Grant) in the amount of 150 thousand euros. This grant funds researchers previously supported by the European Research Council, and enables them to advance their ideas from the groundbreaking research stage towards practical applications of the findings, including early stages of commercial use.
This is not the first time that Prof. Popobzer has won a grant from the European Union. In March 2022 she won a grant Consolidator Grant of the Council for the innovative research project BrainCRISPR, who presented an innovative gold nanoplatform for the introduction of biomolecules CRISPR into the brain, in order to cure rare genetic brain diseases.
More of the topic in Hayadan:
